CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CAR-T 中的凝血病：关键关切还是一过性现象？
英文原题：Coagulopathy in CAR-T: Critical concern or mere blip?
查看英文原题
Coagulopathy in CAR-T: Critical concern or mere blip?
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
评论指出，尽管Peng等人全面综述了CAR-T 相关凝血病的临床和实验室表现，现有文献在术语和分级标准方面仍不够明确，凝血异常的临床意义也可能尚未厘清。为统一临床处理方式，仍需明确的风险分层与预防建议。本文为Peng等发表于《英国血液学杂志》2024年关于血液恶性肿瘤CAR-T 治疗相关凝血异常综述的评论。
展开英文摘要原文
Despite Peng and colleagues providing an extensive review of the clinical and laboratory aspects of CAR-T-associated coagulopathy, the current literature often lacks specificity in nomenclature and gradings, and the clinical implications of coagulopathy may remain unclear. Clear recommendations on stratification and prophylaxis are still required to standardize the clinical approach to this topic. Commentary on: Peng et al. Coagulation abnormalities associated with CAR-T therapy in hematological malignancies: A review. Br J Haematol 2024;205:420-428.
论文信息
- 作者
- Galli E、Sorà F、Rossi E
- 单位
- Dipartimento di Scienze di Laboratorio ed Ematologiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.Italy
- 期刊
- British journal of haematology2024 Aug
- 原文标识
- PubMed 38938123 · DOI 10.1111/bjh.19619